The Study
SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways
This study tested a medicine in mice and lab-grown human blood vessel cells to see how it might work inside tiny blood vessels after a heart attack. It shows what might happen in a test tube or mouse, but we don’t know if it works the same way in real people.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
A diabetes medicine called dapagliflozin helps protect tiny blood vessels in the heart after they get damaged during a heart attack by fixing calcium leaks and reducing stress in the vessel walls.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 58 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — protecting heart blood vessels after a heart attack can prevent further damage and improve survival, even if the heart muscle itself isn't directly treated.
- 2In mice and human cells, the drug reduced cell death and swelling in heart blood vessels by 30-50% (estimated from described effects), and blocked key damage pathways.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Theranostics
Year
2022
Authors
Li Ma, Rongjun Zou, Wanting Shi, Na Zhou, Shaoxian Chen, Hao Zhou, Xinxin Chen, Yueheng Wu
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.